We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA failed to act on Amgen’s investigational chronic immune thrombocytopenia purpura (ITP) treatment Nplate by its July 23 action date — even after it extended the review time for the product by three months.